Market research
6190.TSE PhoenixBio Co., Ltd
TSE JPY Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 1B
- P/E ratio
- 84.55
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.37
Profile
Instrument facts
- Exchange
- TSE
- Currency
- JPY
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- JP3803010002
- Market cap
- 1B
- P/E ratio
- 84.55
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.37
About
About PhoenixBio Co., Ltd
PhoenixBio Co., Ltd. provides contract testing services for pharmaceutical development in Japan, the United States, Europe, and internationally. The company offers PXB-mouse, a chimeric mouse with a humanized liver; and PXB-cells, a human hepatocyte for studies which require the use of primary human hepatocytes, such as drug metabolism, enzyme induction/inhibition, safety assessment, transporter evaluation, anti-HBV therapeutics efficacy testing, and other studies. Its products are used in gene therapeutics, MASH/MAFLD, viral hepatitis, DMPK/toxicity, and custom transplantations applications. PhoenixBio Co., Ltd. was incorporated in 2002 and is headquartered in Higashihiroshima, Japan.
Research context
PhoenixBio Co., Ltd appears in PyInvesting’s Tokyo Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- JPY
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 6190.TSE discussion.
5 years, 7 months ago
PhoenixBio Co., Ltd is currently in a long term uptrend where the price is trading 2.7% above its 200 day moving average.
From a valuation standpoint, the stock is 97.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.1.
PhoenixBio Co., Ltd's total revenue sank by 35.9% to $200M since the same quarter in the previous year.
Its net income has dropped by 185.1% to $-80M since the same quarter in the previous year.
Based on the above factors, PhoenixBio Co., Ltd gets an overall score of 2/5.